MinervaX and Wacker Biotech Announce Manufacturing Collaboration for Prophylactic Vaccine Targeting Group B Streptococcus
MinervaX scaling up supply of novel GBS vaccine, ahead of phase III studies Wacker Biotech to manufacture active vaccine protein ingredients and prepare for commercial supply after regulatory approval Vaccine to address the unmet medical burden of GBS, both by maternal vaccination to prevent adverse pregnancy outcomes and life-threatening infections in infants and by vaccination...